The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Nakao, N., Yoshimura, A., Morita, H., Takada, M., Kayano, T., & Ideura, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12229-5 · Cited by 970
RetractedBrenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
Epstein, F. H., Brenner, B. M., Meyer, T. W., & Hostetter, T. H. (1982) · New England Journal of Medicine · doi:10.1056/nejm198209093071104 · Cited by 2,075
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., & Zucchelli, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341502 · Cited by 1,766
Cited by
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
Anavekar, N. S., McMurray, J. J. V., Velazquez, E. J., Solomon, S. D., Kober, L., Rouleau, J.-L., White, H. D., Nordlander, R., Maggioni, A., Dickstein, K., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041365 · Cited by 1,917
Physiology of Local Renin-Angiotensin Systems
Paul, M., Poyan Mehr, A., & Kreutz, R. (2006) · Physiological Reviews · doi:10.1152/physrev.00036.2005 · Cited by 1,739
Angiotensin II revisited: new roles in inflammation, immunology and aging
Benigni, A., Cassis, P., & Remuzzi, G. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000080 · Cited by 757
“ACE is a circulating enzyme that also degrades bradykinin to inactive fragments, reducing the serum levels of endogenous vasodila- tors (Brewster & Perazella, 2004; Fleming, 2006).”
BackgroundRenin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies
Patel, S., Rauf, A., Khan, H., & Abu-Izneid, T. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.091 · Cited by 626
Devaux, C. A., Rolain, J.-M., & Raoult, D. (2020) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2020.04.015 · Cited by 476
The severe cardiorenal syndrome: ‘Guyton revisited’
Bongartz, L. G., Cramer, M. J., Doevendans, P. A., Joles, J. A., & Braam, B. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi020 · Cited by 460
Sayed-Tabatabaei, F. A., Oostra, B. A., Isaacs, A., van Duijn, C. M., & Witteman, J. C. M. (2006) · Circulation Research · doi:10.1161/01.res.0000223145.74217.e7 · Cited by 353
Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach
Lautrette, A., Li, S., Alili, R., Sunnarborg, S. W., Burtin, M., Lee, D. C., Friedlander, G., & Terzi, F. (2005) · Nature Medicine · doi:10.1038/nm1275 · Cited by 343
The RAAS in the pathogenesis and treatment of diabetic nephropathy
Ruggenenti, P., Cravedi, P., & Remuzzi, G. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.58 · Cited by 319
Incidence and Characteristics of Angioedema Associated With Enalapril
Kostis, J. B., Kim, H. J., Rusnak, J., Casale, T., Kaplan, A., Corren, J., & Levy, E. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.14.1637 · Cited by 291
The renin-angiotensin-aldosterone system, glucose metabolism and diabetes
Giacchetti, G., Sechi, L. A., Rilli, S., & Carey, R. M. (2005) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2005.02.003 · Cited by 267
Sullivan, J. C., Semprun-Prieto, L., Boesen, E. I., Pollock, D. M., & Pollock, J. S. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00429.2007 · Cited by 96
“Activation of AT1 receptors mediates most of the well-known biological functions of ANG II, including vasoconstriction, inflammation, and production of reactive oxygen species (3).”
Salman, I. M. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0625-x · Cited by 66
Devaux, C. A., & Camoin-Jau, L. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1042200 · Cited by 20
“Ang II, inactivates the vasodilator bradykinin and can control the ion-fluid balance by acting on the adrenal cortex to stimulate the release of aldosterone, leading to sodium and water retention (Jaspard et al., 1993; Brewster and Perazella, 2004; Xue et al., 2012; Aroor et al., 2016; Nishimura, 2017).”
Background
Metadata
- Authors
- Brewster, U. C., & Perazella, M. A.
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 2004-02
- Volume
- 116
- Issue
- 4
- Pages
- 263-272
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W2036960544
- Cited by
- 390
- References
- 66
- FWCI
- 14.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.